Skip to main content

GS-US-419-4015 A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

NCT02914561

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study Evaluating the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)

Associated Conditions

Inflammatory Bowel Disease (IBD)

Principal Investigator

Sponsor

Gilead Sciences

You have been asked to be part of this study because you have been diagnosed with Crohn’s disease, which is an inflammatory disease of the gastrointestinal tract (digestive tract). The purpose of this study is to see if filgotinib is effective and safe in treating people that have inflammation in at least one section of their small bowel as part of their Crohn’s disease. The small bowel is part of the digestive tract that connects to the stomach at one end and the colon (large bowel) at the other and consists of sections called the duodenum, jejunum, and ileum. In this study, pictures taken with Magnetic Resonance Enterography (MRE) will be used to make scores of how bad your Crohn’s disease is. The scores will be checked at the beginning and the end of the study. There will be no endoscopy (camera into the rectum or the mouth to look at the digestive tract) required for participation this study.